Midostaurin (Rydapt®) is indicated as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM AHN), or mast cell leukaemia (MCL).
|NCPE Assessment Process||Suspended|
|Rapid review commissioned||13/08/2018|
|Rapid review completed||10/09/2018|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of midostaurin compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by HSE||19/09/2018|
|Pre-submission consultation with Applicant||16/10/2018|
|Current status||This appraisal has been suspended until further evidence and analyses are included in a re-submission. An update on the appraisal and associated timelines will be provided in due course.|